• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.确定 HAM-A 用于轻度、中度和重度广泛性焦虑障碍的截断值。
Int J Methods Psychiatr Res. 2010 Dec;19(4):223-32. doi: 10.1002/mpr.323. Epub 2010 Aug 18.
2
Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.阿吡哌隆缓释剂治疗伴焦虑的抑郁症:来自重度抑郁症患者回顾性亚组分析的证据
J Clin Psychiatry. 2004 Aug;65(8):1069-75.
3
Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.鲁拉西酮用于治疗伴有混合特征和焦虑的重度抑郁症:一项随机、安慰剂对照研究的事后分析
CNS Spectr. 2017 Apr;22(2):236-245. doi: 10.1017/S1092852917000074. Epub 2017 Mar 30.
4
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.用氟西汀治疗伴有共病焦虑症的抑郁症患者。
J Psychopharmacol. 2002 Sep;16(3):215-9. doi: 10.1177/026988110201600304.
5
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.文拉法辛缓释胶囊治疗非抑郁广泛性焦虑障碍门诊患者的疗效:一项为期6个月的随机对照试验。
JAMA. 2000 Jun 21;283(23):3082-8. doi: 10.1001/jama.283.23.3082.
6
Novel Augmentation Strategies in Major Depression.重度抑郁症的新型强化治疗策略
Dan Med J. 2017 Apr;64(4).
7
An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).抗焦虑药SC 48,274用于广泛性焦虑症(GAD)的评估。
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):685-94. doi: 10.1016/0278-5846(94)90076-0.
8
Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder.每日一次的富马酸喹硫平缓释片治疗不同严重程度广泛性焦虑症患者的疗效
Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.
9
Generalized anxiety disorder and the Hamilton Anxiety Rating Scale in Parkinson's disease.帕金森病中的广泛性焦虑障碍与汉密尔顿焦虑量表
Arq Neuropsiquiatr. 2010 Aug;68(4):495-501. doi: 10.1590/s0004-282x2010000400005.
10
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression.精神分裂情感障碍临床整体印象严重程度量表与躁狂和抑郁的既定情绪量表之间的关系。
J Affect Disord. 2013 Aug 15;150(1):17-22. doi: 10.1016/j.jad.2013.01.047. Epub 2013 Mar 18.

引用本文的文献

1
Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.MM120(麦角酰二乙胺)单药治疗广泛性焦虑症:一项随机临床试验。
JAMA. 2025 Sep 4. doi: 10.1001/jama.2025.13481.
2
Proportion and related factors of depression and anxiety for patients with pulmonary nodules in China: a outpatient-based cross-sectional study.中国肺结节患者抑郁和焦虑的比例及相关因素:一项基于门诊的横断面研究。
Sci Rep. 2025 Aug 31;15(1):32029. doi: 10.1038/s41598-025-17911-4.
3
Mental Health and Cognitive Outcomes in Patients Six Months After Testing Positive Compared with Matched Patients Testing Negative for COVID-19 in a Non-Hospitalized Sample: A Matched Retrospective Cohort Study.非住院样本中新冠病毒检测呈阳性患者与匹配的检测呈阴性患者六个月后的心理健康和认知结果:一项匹配的回顾性队列研究
Int J Environ Res Public Health. 2025 Aug 9;22(8):1249. doi: 10.3390/ijerph22081249.
4
Cross-Cultural Differences and Clinical Presentations in Burning Mouth Syndrome: A Cross-Sectional Comparative Study of Italian and Romanian Outpatient Settings.灼口综合征的跨文化差异与临床表现:意大利和罗马尼亚门诊环境的横断面比较研究
J Clin Med. 2025 Aug 16;14(16):5805. doi: 10.3390/jcm14165805.
5
Prevalence and correlates of suicide attempts in working-age, first-episode, drug-naïve major depressive disorder patients.工作年龄首次发作、未使用过药物的重度抑郁症患者自杀未遂的患病率及其相关因素
BMC Psychiatry. 2025 Aug 8;25(1):776. doi: 10.1186/s12888-025-07163-x.
6
Hypoactivity of the Prefrontal Cortex During Go/No-Go Task in Patients With Generalized Anxiety Disorder.广泛性焦虑症患者在“Go/No-Go任务”期间前额叶皮质活动减退
Depress Anxiety. 2025 Jul 28;2025:9040115. doi: 10.1155/da/9040115. eCollection 2025.
7
Prevalence and pattern of cognitive dysfunction in young adults and middle-aged patients with type-2 diabetes.2型糖尿病青年及中年患者认知功能障碍的患病率及模式
J Family Med Prim Care. 2025 Jun;14(6):2527-2537. doi: 10.4103/jfmpc.jfmpc_1900_24. Epub 2025 Jun 30.
8
The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders compared with diagnosis-specific protocols for anxiety disorders: A three-year follow-up.与焦虑症的诊断特异性方案相比,情绪障碍跨诊断治疗统一方案的三年随访。
J Mood Anxiety Disord. 2023 Sep 16;3:100024. doi: 10.1016/j.xjmad.2023.100024. eCollection 2023 Oct.
9
Maternal mental health improvement in ghana: role of green spaces exposure.加纳孕产妇心理健康改善:接触绿色空间的作用。
BMC Womens Health. 2025 Jul 5;25(1):328. doi: 10.1186/s12905-025-03886-x.
10
Altered perfusion in the locus coeruleus of patients with chronic migraine: a pilot 3D-PCASL study.慢性偏头痛患者蓝斑核灌注改变:一项3D-PCASL初步研究
Brain Imaging Behav. 2025 Jun 3. doi: 10.1007/s11682-025-01020-x.

本文引用的文献

1
Estimation of symptom-free days in generalized anxiety disorder.广泛性焦虑障碍中无症状天数的估计。
Curr Med Res Opin. 2006 Mar;22(3):587-91. doi: 10.1185/030079906X96245.
2
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.一项关于帕罗西汀、地昔帕明或安慰剂用于患有重度抑郁症的乳腺癌患者(I、II、III和IV期)的双盲、多中心、平行组研究。
J Clin Psychiatry. 2006 Feb;67(2):288-96. doi: 10.4088/jcp.v67n0217.
3
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.艾司西酞普兰长期治疗广泛性焦虑障碍的安全性和有效性。
J Clin Psychiatry. 2005 Nov;66(11):1441-6. doi: 10.4088/jcp.v66n1115.
4
Open-label trial of riluzole in generalized anxiety disorder.利鲁唑治疗广泛性焦虑症的开放标签试验。
Am J Psychiatry. 2005 Dec;162(12):2379-81. doi: 10.1176/appi.ajp.162.12.2379.
5
Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction.显性和亚临床甲状腺功能障碍患者的抑郁、焦虑、健康相关生活质量及残疾情况
Arch Med Res. 2006 Jan;37(1):133-9. doi: 10.1016/j.arcmed.2005.05.008.
6
The efficacy of divalproex sodium in the treatment of agitation associated with major depression.丙戊酸钠治疗与重度抑郁症相关的激越的疗效。
J Clin Psychopharmacol. 2005 Oct;25(5):476-9. doi: 10.1097/01.jcp.0000177552.21338.b0.
7
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.普瑞巴林治疗广泛性焦虑障碍:一项为期4周的普瑞巴林与阿普唑仑多中心、双盲、安慰剂对照试验
Arch Gen Psychiatry. 2005 Sep;62(9):1022-30. doi: 10.1001/archpsyc.62.9.1022.
8
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.一项关于喹硫平治疗双相I型或II型抑郁症的随机、双盲、安慰剂对照试验。
Am J Psychiatry. 2005 Jul;162(7):1351-60. doi: 10.1176/appi.ajp.162.7.1351.
9
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.德洛环烷治疗广泛性焦虑症:一项安慰剂对照、双盲、剂量探索研究。
Eur Neuropsychopharmacol. 2005 Dec;15(6):617-23. doi: 10.1016/j.euroneuro.2005.03.002. Epub 2005 Jun 9.
10
Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy.确定糖尿病周围神经病变所致轻度、中度和重度疼痛的切点。
Pain. 2005 May;115(1-2):29-36. doi: 10.1016/j.pain.2005.01.028.

确定 HAM-A 用于轻度、中度和重度广泛性焦虑障碍的截断值。

Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.

机构信息

Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD 20814, USA.

出版信息

Int J Methods Psychiatr Res. 2010 Dec;19(4):223-32. doi: 10.1002/mpr.323. Epub 2010 Aug 18.

DOI:10.1002/mpr.323
PMID:20718076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6878292/
Abstract

The aim of the current study was to identify and evaluate cutoffs for mild, moderate, and severe ranges of Hamilton Anxiety Rating Scale (HAM-A) scores. Data were from a four-week randomized trial of treatment for generalized anxiety disorder. Measures included the HAM-A, SF-36, Hospital Anxiety and Depression Scale (HADS), and Clinical Global Impressions of Severity (CGI-S) scale. HAM-A cutoffs were identified based on literature review, expert panel input, and MANOVA models. The optimal cutoff set was evaluated based on association with clinician CGI-S ratings. The sample included 144 patients (56.3% female; 73.6% white; mean age = 35.7 years; mean baseline HAM-A score = 23.7). The optimal HAM-A score ranges were: mild anxiety = 8-14; moderate = 15-23; severe ≥ 24 (scores ≤ 7 were considered to represent no/minimal anxiety). Analysis of variance (ANOVA) models found statistically significant differences among these groups in the SF-36 and HADS. The HAM-A severity ranges closely corresponded to clinicians' CGI-S ratings. The study represents the first step towards developing severity ranges for the HAM-A. These cutoffs should be used with caution and validated in larger samples. If the proposed cutoffs are accepted for general use, they could make results more meaningful and interpretable for researchers, clinicians, and patients.

摘要

本研究旨在确定和评估汉密尔顿焦虑量表(HAM-A)评分轻度、中度和重度范围的截断值。数据来自广泛性焦虑障碍四周随机治疗试验。测量包括 HAM-A、SF-36、医院焦虑和抑郁量表(HADS)和临床总体印象严重度量表(CGI-S)。HAM-A 截断值基于文献回顾、专家小组意见和 MANOVA 模型确定。最优截断值集基于与临床医生 CGI-S 评分的关联进行评估。样本包括 144 名患者(56.3%为女性;73.6%为白人;平均年龄为 35.7 岁;基线 HAM-A 平均得分为 23.7)。最优 HAM-A 评分范围为:轻度焦虑=8-14;中度=15-23;重度≥24(得分≤7 被认为代表无/轻度焦虑)。方差分析(ANOVA)模型发现这些组在 SF-36 和 HADS 中的差异具有统计学意义。HAM-A 的严重程度范围与临床医生的 CGI-S 评分密切相关。该研究代表了为 HAM-A 制定严重程度范围的第一步。这些截断值应谨慎使用,并在更大的样本中进行验证。如果接受提议的截断值用于一般用途,它们可以使研究人员、临床医生和患者的结果更有意义和可解释。